Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Idrugs : the Investigational Drugs Journal|December 22, 2009
HDAC Inhibitors--CHI's Third Annual ConferenceRoberto R Rosato
Expert Opinion on Investigational Drugs|December 19, 2003
Histone deacetylase inhibitors in clinical developmentRoberto R Rosato, Steven Grant
Expert Opinion on Therapeutic Targets|August 9, 2005
Histone deacetylase inhibitors: insights into mechanisms of lethalityRoberto R Rosato, Steven Grant
Cancer Biology & Therapy|April 4, 2003
Histone deacetylase inhibitors in cancer therapyRoberto R Rosato, Steven Grant
Cancer Research|July 4, 2003
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1Roberto R Rosato, Jorge A Almenara, Steven Grant
Antibiotics (Basel, Switzerland)|November 27, 2021
Staphylococcus pseudintermedius's PBP4 Is Directly Associated with the Dissociated Oxacillin and Cefoxitin PhenotypePaula Gagetti, Roberto R Rosato, Adriana E Rosato
Antimicrobial Agents and Chemotherapy|May 4, 2011
Fate of mutation rate depends on agr locus expression during oxacillin-mediated heterogeneous-homogeneous selection in methicillin-resistant Staphylococcus aureus clinical strainsKonrad B Plata, Roberto R Rosato, Adriana E Rosato
Molecular Cancer Therapeutics|January 7, 2004
Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cellsRoberto R Rosato, Jorge A Almenara, Yun Dai, et al.
Cancer Research|October 3, 2007
The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulationRoberto R Rosato, Jorge A Almenara, Stefanie Coe, et al.
Molecular Pharmacology|February 24, 2004
Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridolRoberto R Rosato, Jorge A Almenara, Chunrong Yu, et al.
Pageof 5